Targets › BAG3
3 programs from 3 companies in 3 trials: 3 Phase 1; Cardiovascular; next expected readout Dec 2028.
Co-chaperone and adapter protein that connects different classes of molecular chaperones including heat shock proteins 70 (HSP70s), e.g. HSPA1A/HSP70 or HSPA8/HSC70, and small heat shock proteins (sHSPs), e.g. (UniProt, O95817)
Open in Phaseline: the race on BAG3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Affinia Therapeutics | AFTX-201 AAV gene therapy delivering BAG3 transgene | BAG3 | Phase 1 | Dilated Cardiomyopathy (DCM) | Dec 2028 |
| Rocket Pharmaceuticals | RP-A701 AAV gene therapy delivering BAG3 transgene via AAVrh.74 capsid | BAG3 | Phase 1 | Dilated Cardiomyopathy (DCM) | Jun 2029 |
| AstraZeneca | ALXN2350 AAV9-mediated BAG3 gene therapy | BAG3 | Phase 1 | BAG3 Mutation Associated Dilated Cardiomyopathy | Jan 2032 |
Dilated Cardiomyopathy (DCM) (2) BAG3 Mutation Associated Dilated Cardiomyopathy (1)
other (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.